Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devan Kansagara

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Annals of Internal Medicine|August 27, 2020
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|January 4, 2021
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|September 21, 2020
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|November 30, 2020
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|July 24, 2020
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|February 7, 2022
Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|April 26, 2021
Update Alert 8: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|May 6, 2024
Update Alert: Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of PhysiciansChelsea Ayers, Rachel Ward, Devan Kansagara
Annals of Internal Medicine|March 20, 2023
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|October 26, 2020
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Annals of Internal Medicine|August 27, 2020
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|January 4, 2021
Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|September 21, 2020
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|November 30, 2020
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|July 24, 2020
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|February 7, 2022
Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|April 26, 2021
Update Alert 8: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|May 6, 2024
Update Alert: Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of PhysiciansChelsea Ayers, Rachel Ward, Devan Kansagara
Annals of Internal Medicine|March 20, 2023
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Annals of Internal Medicine|October 26, 2020
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in AdultsKatherine Mackey, Devan Kansagara, Kathryn Vela
Pageof 13